Gastrointestinal Cancer News

Circulating tumor DNA isolated from blood samples in patients with pancreatic adenocarcinoma independently predicted survival, according to prospective study results.

Starting January 1, 2017, Humana will cover Cologuard, the FDA-approved multi-target stool DNA test for noninvasive colorectal cancer screening, as an in-network service for its members, most of whom will have access to the test with no co-pay, the manufacturer announced.

Today, the USPSTF published its sixth annual report on high-priority evidence gaps for clinical preventive services to Congress.

The effect of vitamin D3 supplementation on advanced adenomas, but not overall adenoma risk, varied depending on common differences in the vitamin D receptor gene in a randomized controlled trial.

One in every six patients with colorectal cancer aged younger than 50 years tests positive for at least one inherited genetic mutation that increases cancer risk, according to a statewide Ohio study published in JAMA Oncology.

The FDA granted orphan drug designation to ABTL0812 for the treatment of pancreatic cancer, according to the drug’s manufacturer.

Among patients being treated for breast cancer, lymphoma or gastric cancer with anthracycline-based chemotherapy, cardiotoxicity from the treatment was most pronounced in those with CV risk factors, especially diabetes, according to new data.

Highly effective immunotherapies and targeted treatments have dramatically improved outcomes for patients with many types of solid tumors.

In contrast to the steady increase in survival for most cancers, advances have been slow for pancreatic cancers.

Click here to read the Cover Story, “Greater collaboration, understanding of disease biology may improve outcomes in pancreatic cancer.”